LUNG CANCER
Latest News
Latest Videos
CME Content
More News
The FDA has granted an orphan drug designation to durvalumab (Imfinzi) for the treatment of patients with small cell lung cancer (SCLC).<br />
Hussain Borghaei, DO, MS, discusses the significance of the overall survival data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced non–small cell lung cancer.
In an interview with Targeted Oncology, David Spigel, MD, discussed the updated findings from the PACIFIC trial and how these data will impact the treatment landscape for patients with stage III NSCLC, as well as those with earlier-stage disease. He also highlighted controversies that clinicians face with incorporating immunotherapy into their practice for patients.
Treatment with erlotinib significantly extended progression-free survival in patients with stage IIIA-N2 <em>EGFR-</em>mutant non–small cell lung cancer compared with a combined chemotherapy regimen of gemcitabine plus cisplatin, according to clinical trial results published recently in the <em>Journal of Clinical Oncology</em>.
Biomarker expansion has enjoyed a boom since 2006, with patient incidence of positive biomarkers reaching up to 50% in non–small cell lung cancer and melanoma and 25% in acute myeloid leukemia and myelodysplastic syndromes, according to the <em>Global Oncology Trends 2018</em> report.
A new study shows comparability between liquid biopsy and tissue biopsy in both diagnostics and monitoring of non–small cell lung cancer (NSCLC). However, based on the results, liquid biopsies may be preferable to help oncologists make swifter decisions that help manage the disease.<br />
In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for bevacizumab across several indications.
The FDA has approved Zirabev, a biosimilar to bevacizumab for 5 indications. Zirabev has been approved for the treatment of patients with metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non–small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Frontline durvalumab led to a statistically significant and clinically meaningful improvement in overall survival (OS) in combination with etoposide and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer, according to the results of a planned interim analysis of the phase III CASPIAN trial.
David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, director of the Lung cancer Research Program, and member of the Association of Community Cancer Centers explains to <em>Targeted Oncology, </em>the ways in which ACCC is improving the care landscape and outcomes for patients with advanced non–small cell lung cancer.
In an interview with <em>Targeted Oncology, </em>Shirish Gadgeel, MBBS, of the Department of Medicine, Hematology/Oncology Division, University of Michigan, discussed recent study updates from the phase III KEYNOTE-189 trial and potential implications for the combination on clinical practice.
During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Mary Jo J. Fidler, MD, reviewed treatment options in the first and second line based on a case study of a patient with NSCLC who experiences rapid progression on her first-line regimen.
The first regulatory approval has been granted to entrectinib in Japan. The Japanese Ministry of Health, Labour and Welfare recently approved the agent for the treatment of adult and pediatric patients with <em>NTRK </em>fusion–positive, advanced recurrent solid tumors.
The American Cancer Society, Dana-Farber Cancer Institute, Baptist Cancer Center, and the Mayo Clinic report that treatment patterns varied markedly by cancer type and care facility setting for patients with de novo metastatic disease who died within 1 month after diagnosis, based on an analysis of data from 100,848 patients collected from the National Cancer Database, a hospital-based cancer registry that captures 70% of patients in the United States with a new diagnosis.